In a research note published August 14, Roth Capital analyst Ed Arce affirmed a Buy rating on shares of Conatus Pharmaceuticals (CNAT) with a $19.00 price target, following the company’s …
BioCryst Pharmaceuticals (BCRX) today announced the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct Phase I clinical human safety …
In a research note issued August 6, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (BCRX) with a $20 …
In a research note published yesterday, Roth Capital analyst Ed Arce reaffirmed a Buy rating on Acura Pharmaceuticals (ACUR) with a $2.50 price …
Last week, July 30, Durata Therapeutics (DRTX) announced a commercialization agreement for Dalvance (dalbavancin) with Angelini across much of Southern and Eastern Europe, Russia and Turkey. The …
In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) and reduced his price target to $16 (from $22), following …
In reaction to Durata Therapeutics’s (DRTX) announcement that it has began shipping Dalvance to its distributors, Roth Capital analyst Ed Arce reaffirmed a …
In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a $22 price target, which represents 121% upside to the current share …
In a research report released yesterday, Roth Capital analyst Ed Arce reiterated a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a price …
In a research report released today, Roth Capital analyst Ed Arce raised his price target on Durata Therapeutics (DRTX) to $28 (from $24), while maintaining a Buy rating on the stock. The new price target …
